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IMPORTANCE The dopamine hypothesis suggests that dopamine abnormalities underlie
psychosis, irrespective of diagnosis, implicating dopamine dysregulation in bipolar affective
disorder and schizophrenia, in line with the research domain criteria approach. However, this
hypothesis has not been directly examined in individuals diagnosed with bipolar disorder
with psychosis.
OBJECTIVES To test whether dopamine synthesis capacity is elevated in bipolar disorder with
psychosis and how this compares with schizophrenia andmatched controls and to examine
whether dopamine synthesis capacity is associated with psychotic symptom severity,
irrespective of diagnostic class.
DESIGN, SETTING, AND PARTICIPANTS This cross-sectional case-control positron emission
tomographic study was performed in the setting of first-episode psychosis services in an
inner-city area (London, England). Sixty individuals participated in the study (22 with bipolar
psychosis [18 antipsychotic naive or free], 16 with schizophrenia [14 antipsychotic naive or
free], and 22matched controls) and underwent fluorodihydroxyphenyl-L-alanine
([18F]-DOPA) positron emission tomography to examine dopamine synthesis capacity.
Standardized clinical measures, including the Positive and Negative Syndrome Scale, Young
Mania Rating Scale, and Global Assessment of Functioning, were administered. The study
dates were March 2013 to November 2016.
MAIN OUTCOMES ANDMEASURES Dopamine synthesis capacity (Kicer) and clinical measures
(Positive and Negative Syndrome Scale, YoungMania Rating Scale, and Global Assessment of
Functioning).
RESULTS Themean (SD) ages of participants were 23.6 (3.6) years in 22 individuals with
bipolar psychosis (13 male), 26.3 (4.4) years in 16 individuals with schizophrenia (14 male),
and 24.5 (4.5) years in controls (14 male). There was a significant group difference in striatal
dopamine synthesis capacity (Kicer) (F2,57 = 6.80, P = .002). Ki
cer was significantly elevated in
both the bipolar group (mean [SD], 13.18 [1.08] × 10−3 min−1; P = .002) and the schizophrenia
group (mean [SD], 12.94 [0.79] × 10−3 min−1; P = .04) compared with controls (mean [SD],
12.16 [0.92] × 10−3 min−1). There was no significant difference in striatal Kicer between the
bipolar and schizophrenia groups. Kicer was significantly positively correlated with positive
psychotic symptom severity in the combined bipolar and schizophrenia sample experiencing
a current psychotic episode, explaining 27% of the variance in symptom severity (n = 32,
r = 0.52, P = .003). There was a significant positive association between Kicer and positive
psychotic symptom severity in individuals with bipolar disorder experiencing a current
psychotic episode (n = 16, r = 0.60, P = .01), which remained significant after adjusting for
manic symptom severity.
CONCLUSIONS AND RELEVANCE These findings are consistent with a transdiagnostic role for
dopamine dysfunction in the pathoetiology of psychosis and suggest dopamine synthesis
capacity as a potential novel drug target for bipolar disorder and schizophrenia.
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P sychotic illnesses, suchas schizophreniaandbipolar af-fectivedisorder,haveacombined lifetimeprevalenceofapproximately 3%.1 The researchdomain criteria initia-
tive fromtheNational Institute ofMentalHealthproposes that
common neurobiological mechanisms underlie symptom do-
mains across disorders.2 The neuromodulator dopamine has
been implicated in the pathophysiology of psychosis in
schizophrenia3-9 andpsychosis inotherdisorders.10 Investiga-
tions using positron emission tomography (PET) have demon-
strated increased striatal dopamine synthesis capacity in
schizophrenia.11 Dopamine synthesis capacity is also elevated
in individuals at high clinical risk of psychosis,12-16 some of
whommaydevelopbipolar affectivedisorderwithpsychosis,17
andin individualswithpsychosis inthecontextof temporal lobe
epilepsy.10These findings suggest thatelevateddopaminesyn-
thesis capacity may be transdiagnostic, underlying psychosis
across disorders, rather than specific to schizophrenia. Evi-
dencealso suggests thatdopaminedysfunction increaseswith
development of psychosis15 and is greater in acute psychosis
relative to remission,9 suggesting a state component.
Bipolar affective disorder has an approximate lifetime
prevalenceof 1%,18 andabouthalf of thepatientsdeveloppsy-
chosis, predominantly in themanic phase.19 Psychotic symp-
toms in bipolar affective disorder respond to antipsychotic
drugs (dopamine D2/D3 blockers), suggesting that a dopami-
nergic abnormality couldunderlie these symptoms.20-33Dopa-
mine synthesis capacity is unaltered in bipolar disorderwith-
out psychosis,34 although it remains unclear if dopamine
synthesis capacity is altered in individualswith bipolar disor-
derwith a history of psychosis, whether this is related to psy-
chotic symptoms, or how this compares with schizophrenia.
Therefore, we sought to investigate dopamine synthesis
capacity indexedusingfluorodihydroxyphenyl-L-alanine([18F]-
DOPA) PET imaging in individualswith bipolar psychosis.We
hypothesized that (1) individualswithbipolarpsychosiswould
have elevated striatal dopamine synthesis capacity com-
pared with matched healthy controls and that this elevation
would be comparable to that in schizophrenia and (2) striatal
dopamine synthesis capacity would positively correlate with
psychotic symptom severity in individuals currently experi-
encing psychosis, irrespective of diagnosis, in line with evi-
dence linking dopamine dysregulation to psychotic state.9,15
Methods
Ethical permission was obtained from the local ethics com-
mittee (East of England–Cambridge East National Health Ser-
viceResearchEthicsCommittee) for this cross-sectional case-
control study. All participants provided written informed
consent to be included in the study. An a priori power calcu-
lation inG*powerwasused todetermine theminimumsample
size (eAppendix in the Supplement). The study dates were
March 2013 to November 2016.
Participants
Patients with bipolar disorder were recruited from first-
episode psychosis services in an inner-city area (London, En-
gland).Theywereeligiblefor inclusioninthestudyif they(1)met
diagnostic (DSM-IV) criteria for bipolar affective disorder type
IasassessedbytheStructuredClinical InterviewforDSM-IVAxis
I disorders,35 (2) had at least one current or previous psychotic
episode(definedbelow),and(3)demonstratednoevidencethat
symptomswere drug induced.
Individuals with schizophrenia were recruited from the
same first-episode psychosis services, matched with the bi-
polar group for age (within 5 years). They were eligible for
inclusion in the study if they (1)met theStructuredClinical In-
terview for DSM-IV Axis I disorders35 criteria for schizophre-
nia, (2) had at least one current or previous psychotic episode
as defined below, and (3) demonstrated no evidence that the
symptoms were drug induced.
A psychotic episode was defined as at least moderate se-
verity on one ormore of the delusion (P1), hallucination (P3),
and persecution (P6) items on the Positive and Negative Syn-
dromeScale (PANSS) lasting for at least 1week, consistentwith
research definitions.17 We excluded the conceptual disorga-
nization item, which could be confounded by mania.
Age-matched (within 5 years) healthy controls were
recruited contemporaneously from the same geographical
area through advertisements in local media. Healthy volun-
teers had no previous or current history of psychiatric illness
(assessed by the Structured Clinical Interview for DSM-IV
Axis I disorders),35 no concurrent psychotropic medication
use, and no family history of psychosis. Full exclusion crite-
ria are given in the eAppendix in the Supplement.
Clinical Assessments
Participantswere assessedon thedayof thePET scanwith the
PANSS,36GlobalAssessmentofFunctioning (GAF) scale,37 and,
in the bipolar group, YoungMania Rating Scale (YMRS).38 All
patients receivedclinical follow-upforaminimumof18months
to determine diagnostic stability using DSM-IV criteria.
Medication history was recorded. Individuals were sub-
classified as antipsychotic naive (no current or previous treat-
ment), antipsychotic free (not currently taking antipsychotic
medication, with at least 6 weeks’ washout for oral medica-
tion or 6 months’ washout for depot medication), or cur-
rently treated with antipsychotics.39
Key Points
Question Is dopamine synthesis capacity elevated in bipolar
psychosis compared with controls?
Findings In this cross-sectional case-control positron emission
tomographic study of 22 individuals with first-episode bipolar
psychosis, 16 individuals with first-episode schizophrenia, and 22
controls, there was a statistically significant elevation in dopamine
synthesis capacity in those with bipolar psychosis compared with
controls. This difference was similar to that seen in schizophrenia,
and there was a statistically significant association between
positive psychotic symptoms and dopamine synthesis capacity in
the whole sample, explaining 27% of the variance.
Meaning Dopamine synthesis capacity is elevated in bipolar
psychosis and is associated with positive psychotic symptoms,
irrespective of diagnosis.
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[18F]-DOPA PET Imaging
Imaging data were obtained on a PET scanner (Biograph 6
HiRez; Siemens) in 3-D mode. Participants were not permit-
ted to smoke for 4 hours preceding the scan.40 One hour be-
fore the scan, participants received 400mg of entacapone, a
peripheral catechol-O-methyl-transferase inhibitor, and150mg
of carbidopa, aperipheral aromatic aciddecarboxylase inhibi-
tor, toprevent formationof radiolabeledmetabolites thatmay
cross theblood-brainbarrier.41 After acquiring a computed to-
mographic scan for attenuationcorrection, approximately 160
MBqof [18F]-DOPAwas administeredbybolus intravenous in-
jection 30 seconds after the start of PET imaging (eAppendix
in the Supplement).
PET Image Analysis
The region-of-interest analysis was conducted masked to
group status. Our primary end point was the dopamine syn-
thesis capacity (Kicer, written previously as Ki42) in the whole
striatum. In view of evidence that dopaminergic alterations
may bemore marked in schizophrenia in the associative sub-
division of striatum relative to other regions13,43,44 and
elevated in the substantia nigra,44 we also conducted sec-
ondary analyses of these regions. Statistical parametric map-
ping (SPM8; Wellcome Trust Centre for Neuroimaging45) was
used to automatically normalize a tracer-specific tem-
plate,13,46 together with functional striatal and substantia
nigra regions of interest defined in Montreal Neurologic
Institute space,47,48 to each individual PET summation
realigned image. Further details of striatal subdivisions are
given in the eAppendix in the Supplement. The cerebellum
was used as the reference region, defined as per Martinez et
al.48 Kicer was calculated using the Patlak-Gjedde graphical
approach adapted for reference tissue input function, which
has been shown to have good reliability.46 Although the ref-
erence region approach is robust to global differences in
radiotracer delivery to the brain,49 we examined the refer-
ence region (cerebellum) to see whether there was any
change in standardized uptake values in the cerebellum at 95
minutes.
An exploratory voxelwise analysis was conducted to
determine subregional differences in Kicer between groups.
Details are given in the eAppendix in the Supplement.
Statistical Analysis
Statistical analyses were performed using software programs
(Microsoft Excel for Mac, version 15; Microsoft Corp50 and
SPSS, version 23; SPSS Inc51). Normality of distribution was
confirmed using the Shapiro-Wilk test. Independent-sample
t tests for normally distributed data and Mann-Whitney tests
for nonparametric data were used to examine if there were
differences in demographic and clinical variables between
groups.
To test for differences in striatal Kicer between the 3 diag-
nostic groups, we used analysis of variance, with Tukey test
for post hoc pairwise comparisons. To test the association
between Kicer and positive psychotic symptom scores in indi-
viduals experiencing a current psychotic episode (irrespective
of diagnosis), we used Pearson product moment correlation.
In addition, we restricted this analysis to individuals with
bipolar affective disorder and schizophrenia separately. Manic
symptoms may be linked to dopamine dysfunction25,52,53 and
may covary with psychotic symptoms. Therefore, we also
conducted partial correlation with the YMRS as a covariate
(excluding the “content” item on the YMRS, which indexes
psychotic symptoms).
Plotswere inspected for outliers, andCookdistanceof4/n
wasused to identifyoutliers.A2-tailed significance (α) thresh-
old of 0.05 was used throughout.
Results
Demographic and Clinical Characteristics
In total, 22 individuals were included in the bipolar group, 16
individualswere included in the schizophrenia group, and 22
individualswere included in thehealthy control group.All pa-
tients received follow-up,which confirmed that diagnoses re-
mained stable.
Demographicdetails forallparticipantsare listed inTable 1.
There were no significant differences between illness groups
andhealthyvolunteers in age, sex, or radioactive isotopedose
received.
Thereweresignificantdifferencesbetweenthebipolar and
schizophreniagroups inthedurationof illnessandinthePANSS
negative symptom and total symptom scores. These data are
summarized in Table 1.
Sixteen of 22 individuals in the bipolar group and all 16
individuals in the schizophrenia group fulfilled criteria for a
current psychotic episode, with the remainder having a his-
tory of a psychotic episode within the last 2 years. Of the 22
individuals with bipolar psychosis, 18 (10 antipsychotic naive
and 8 antipsychotic free) were not taking antipsychotics at
the time of the PET scan (eAppendix in the Supplement). Of
the 16 individuals with schizophrenia, 14 (11 antipsychotic
naive and 3 antipsychotic free) were not taking antipsychot-
ics at the time of the PET scan (Table 1). Two individuals (one
in the bipolar group and one in the schizophrenia group)
were taking aripiprazole at the time of the PET scan (one for
<2 weeks).
Uptake in the Reference Region andMovement Variables
Across Groups
There was no significant association of group with standard-
ized uptake values in the reference region (eAppendix in the
Supplement). In addition, no significant association of group
withheadmotionwasobservedfor the3conditions,withmean
(SD) values of 13.06 (9.07) mm for the bipolar group, 14.52
(6.46)mmfor the schizophrenia group, and9.61 (9.49)mmfor
the control group (F2,57 = 1.68, P = .20).
Dopamine Synthesis Capacity Across Groups
There was a significant group difference in Kicer in the whole
striatum (F2,57 = 6.80, P = .002) and its functional subdivi-
sions (Table 2). Post hoc comparisons showed that the mean
(SD) Kicer in both the bipolar group (13.18 [1.08] × 10−3 min−1)
and the schizophrenia group (12.94 [0.79] × 10−3 min−1) was
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significantly elevated relative to controls (12.16 [0.92] × 10−3
min−1), with large effect sizes (Cohen d = 1.02, P = .002 in the
bipolar group and Cohen d = 0.91, P = .04 in the schizophre-
nia group). There was no significant difference in Kicer in the
whole striatumbetween thebipolar and schizophrenia groups
(P = .73). Thegroupdifference inKicer remained significant af-
terexcluding individuals takingantipsychoticmedication, leav-
ing 18 in the bipolar group and 14 in the schizophrenia group
(F2,51 = 6.40,P = .003): themean (SD)whole striatal Kicer was
13.17 (1.13) × 10−3min−1 in thebipolar group, 13.00 (0.73) × 10−3
min−1 in the schizophrenia group, and 12.16 (0.92) × 10−3min−1
in thecontrol group.Because theschizophreniagrouphad lon-
ger duration of illness than the bipolar group, we ran a sec-
ondaryanalysisof the relationshipbetweenwhole striatalKicer
and the duration of illness across the patient groups, which
showed no significant relationship (r = −0.05, P = .78).
Voxelwise analysis identified significantly greater Kicer
in the bipolar group relative to controls (peak in the right
caudate) and in the schizophrenia group relative to controls
(peak in the left putamen) (Figure 1). Relative to controls,
the subregional analyses showed significant elevations in all
3 functional striatal subdivisions in the bipolar group but
only a suggestion in the associative striatum in the schizo-
phrenia group, with no differences in the substantia nigra
for either group (eAppendix in the Supplement).
Relationship Between Kicer and Psychotic Symptom Severity
Across Diagnostic Groups
We found a significant association between whole striatal
Kicer and the PANSS positive subscale symptom severity
scores in the combined bipolar and schizophrenia sample of
patients experiencing a current psychotic episode (Figure 2),
explaining 27% of the variance (n = 32, r = 0.52, P = .003).
Cook distance test identified one potential outlier, but
removal of this individual did not affect the significance
(r = 0.49, P = .01). There was no association between whole
Table 1. Study Participant Demographic and Clinical Details
Variable
Bipolar
(n = 22)
Schizophrenia
(n = 16)
Controls
(n = 22) P Value
Age, mean (SD), y 23.6 (3.6) 26.3 (4.4) 24.5 (4.5) .14
Male, No. (%) 13 (59) 14 (88) 14 (64) NA
Medication status, No. (%)
Antipsychotic naive or free 18 (82) 14 (88) NA NA
Naive 10 11 NA NA
Free 8 3 NA NA
Taking antipsychotic 4 (18) 2 (13) NA NA
Race/ethnicity, No.
White 9 5 13 NA
Black 8 7 3 NA
Asian 1 1 4 NA
Mixed 4 3 2 NA
Duration of illness, median
(IQR), mo
12 (19) 24 (24) NA .04
Prior antipsychotic
medication, median (IQR),
chlorpromazine dose-years
0.14 (1.33) 0.05 (0.03) NA .42
Dose of radioactive isotope
injected, mean (SD), MBq
151.37 (13.70) 144.40 (12.29) 154.65 (14.51) .71
PANSS, mean (SD)
Positive symptom score 16.05 (8.22) 18.81 (4.12) NA .18
Negative symptom score 12.27 (5.40) 17.75 (6.32) NA .01
Total symptom score 56.48 (56.68) 72.94 (16.46 NA .01
Global Assessment of
Functioning, mean (SD)
61.73 (15.94) 46.50 (13.06) NA .01
Abbreviations: IQR, interquartile
range (from first to third quartile);
NA, not applicable; PANSS, Positive
and Negative Syndrome Scale.
Table 2. Striatal Kicer by Study Group for the BilateralWhole Striatum and Bilateral Functional
Striatal Subdivisions
Striatal Region
Kicer, Mean (SD), ×10−3 min−1
P value
Bipolar
(n = 22)
Schizophrenia
(n = 16)
Controls
(n = 22)
Whole striatum 13.18 (1.08) 12.94 (0.79) 12.16 (0.92) .002
Associative striatum 13.22 (1.19) 12.95 (0.86) 12.15 (0.89) .002
Limbic striatum 13.05 (0.90) 12.56 (0.81) 11.95 (1.03) .001
Sensorimotor striatum 13.16 (1.13) 13.09 (0.91) 12.31 (1.25) .03 Abbreviation: Ki
cer, dopamine
synthesis capacity.
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striatal Kicer and the PANSS negative or total symptom scores
(r = 0.13, P = .48 and r = 0.30, P = .10, respectively).
SymptomCorrelation in Bipolar Disorder
In thewhole sampleof individualswithbipolar disorder (with
andwithout a current psychotic episode), therewas anonsig-
nificant relationshipbetweenwholestriatalKicer andthePANSS
positive subscale symptom severity score (n = 22, r = 0.42,
P = .05).This relationshipwassignificantwhenthesamplewas
restricted topatientswith bipolar disorderwith a current psy-
chotic episode, explaining 36% of the variance in positive
symptoms (n = 16, r = 0.60, P = .01), and remained signifi-
cant after covarying for the YMRS (excluding the “content”
item) (r = 0.56, P = .046).
SymptomCorrelation in Schizophrenia
Finally, symptom correlation was assessed in the schizophre-
nia group. In thewhole sample of patients with schizophrenia
(all experiencingacurrentpsychoticepisode), therewasnocor-
relation between whole striatal Kicer and the PANSS positive
symptoms (n = 16, r = 0.31, P = .24).
Discussion
Dopamine synthesis capacity was elevated, with a large ef-
fect size (Cohen d = 1.02), in individuals with bipolar affec-
tivedisorder andacurrentorpreviouspsychotic episode com-
paredwith healthy controls. In addition, dopamine synthesis
capacitywas significantly elevated in the schizophrenia group
relative to controls. Moreover, dopamine synthesis capacity
was associatedwith the severity of psychotic symptoms in the
bipolar group, explaining 36% of the variance in psychotic
symptoms. This relationship remained significant after ad-
justing for the severity of manic symptoms.
The finding herein of no difference in Kicer in the substan-
tia nigra between the schizophrenia group and controls differs
from the results byHowes et al.44 However, it should be noted
that our studywas underpowered to detect this influence.
Our finding of a relationship between positive psychotic
symptoms anddopamine synthesis capacity in the combined
bipolar and schizophrenia sample but not in the schizophre-
nia group could be due to a lack of power or inclusion ofmore
patients with longer illness durations in the schizophrenia
group. However, while some studies13,44,54 in schizophrenia
have found relationships with symptoms, other studies55-58
have not, suggesting that further work is needed to disen-
tangle these correlations.
Strengths and Limitations
A strength of our study is the large number of participants
who were antipsychotic naive or free. Furthermore, most
individuals were symptomatic and were experiencing an
acute psychotic episode at the time of the PET scan. The
bipolar and schizophrenia groups were matched for age and
medication status, but by chance the schizophrenia group
had significantly longer duration of illness. However, there
was no relationship between the duration of illness and Kicer
in either group. A concern in first-episode samples is that
diagnoses may change. However, in bipolar disorder, more
than 90% of diagnoses made on initial presentation are
stable 2 years later,59 although diagnoses may be more
dynamic in the early-intervention services that we recruited
Figure 1. Voxelwise Comparison of Striatal Dopamine Synthesis Capacity in the Bipolar Psychosis Group
Relative to the Control Group
0 1
T contrast
2 3 4
Increased striatal dopamine synthesis
capacity was evident in the bipolar
psychosis group (n = 22) relative to
the control group (n = 22). The color
bar shows the t statistic. Themost
significant increase was in the right
caudate (peak at Montreal Neurologic
Institute coordinates x = 8, y = 10,
z = −8; t statistic = 3.96,
familywise-error corrected P = .03).
The image was thresholded at
P < .001 (uncorrected) using a striatal
mask (for illustration purposes only).
The t statistics for the striatal region
are overlaid on a standard structural
template in sagittal (left), coronal
(middle), and axial (right) views.
Figure 2. Relationship Between Striatal Dopamine Synthesis Capacity
(Kicer) and Positive Psychotic SymptomRating in the Bipolar Group
Relative to the Schizophrenia Group
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There was a significant positive correlation between psychotic (positive)
symptom severity and whole striatal Kicer (r = 0.52, P = .003). PANSS indicates
Positive and Negative Syndrome Scale.
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from because they aim to see patients as soon as possible.
On follow-up (minimum of 18 months), none of the indi-
viduals classified as having either bipolar disorder or schizo-
phrenia had their diagnoses changed, and the validity of
diagnosis is strengthened by the difference in negative but
not positive symptoms between groups. We did not detect a
difference in head motion between groups, although it was
greater in absolute terms in the patient groups. Given that
motion, especially in the basal ganglia, causes loss of
resolution,60 any residual motion after motion correction
would reduce Kicer. However, because this would lead to an
underestimate of Kicer, it would not account for our findings.
A potential limitation is the lack of a nonpsychotic con-
trol group given possible nonspecific influences of illness, al-
though a prior [18F]-DOPA study34 in individuals with non-
psychotic mania failed to find a difference compared with
controls. Our studywas not constructed or powered to detect
a difference between bipolar psychosis and schizophrenia.
A small number of individuals were taking antipsychotic
medication. The results of preclinical studies61,62 suggest
that antipsychotic blockade of autoreceptors should cause
increased DOPA uptake. However, these studies generally
used short exposures to antipsychotics, which may not be
equivalent to months of patient exposure. Indeed, there is
evidence from animal investigations that 3 weeks of antipsy-
chotic treatment leads to depolarization, decreasing sponta-
neous firing of dopamine neurons,63 which would reduce
dopamine synthesis. Consistent with this finding, the one
relevant human study64 found that subchronic antipsychotic
treatment reduced [18F]-DOPA uptake in individuals with
schizophrenia, which would not explain our results because
the effect of antipsychotics would mask any difference com-
pared with controls. However, individuals in that study took
only haloperidol for their psychiatric symptoms, and it
remains to be determined in patients what effect other anti-
psychotics have on Kicer. Nonetheless, Kicer remained signifi-
cantly elevated in the patient groups herein when our analy-
sis was restricted to patients who were antipsychotic naive
or free, indicating that our findings are not explained by
direct treatment influences.
Our outcomemeasure, Kicer, indexes the uptake of [18F]-
DOPA intodopamineneurons, aswell as its conversionbyaro-
matic acid decarboxylase into [18F]-dopamine and storage in
terminals.49 Therefore, the increasedKicerwe report likely re-
flects an increase in one ormore of these processes, aswell as
anet increase indopamine synthesis capacity.65However, be-
cause tyrosine hydroxylase, not aromatic acid decarboxyl-
ase, is the rate-limiting step in dopamine synthesis, this in-
terpretationcouldbeaffected if therearealterations in tyrosine
hydroxylase levels or activity. Indeed, reduced tyrosine hy-
droxylase levels could conceivably lead to reduced net dopa-
mine synthesis, despite a compensatory increase in aromatic
acid decarboxylase activity detectable with [18F]-DOPA
imaging.
We did not measure plasma input function. There could
conceivably be alterations in the delivery of [18F]-DOPA, al-
though the reference region approach is robust to global
differences.49Toexclude thispotential confounding factor,we
examined the reference region to see whether there was any
change across groups and found no difference.
Kicer reflects a composite of kinetic parameters, includ-
ingnotonlyblood-tissue transportation (ie,K1 andk2)but also
relative activity of aromatic acid (DOPA) decarboxylase with
respect to [18F]-DOPA (k3) and the elimination of decarboxyl-
ated [18F]-DOPAmetabolites from thebrain (kloss).49,66 There-
fore, while our findings indicate elevation in these aspects of
dopaminergic activity, differencesmeasured forKicer could re-
flect change inoneormoreof theseparameters.However,Kicer
has been shown to correlate well with the [18F]-DOPA decar-
boxylation rate (k3D) derived from the 2-tissue compartmen-
tal model, with a metabolite-corrected arterial plasma input
function inbothnormalandpathological conditions.67,68More-
over, if anybiaswas introduced inKicer estimates by thequan-
tification approach, it is likely to be consistent across all
3 groups in our cross-sectional case-control study. However,
future studies could address this by measuring the arterial
input function.
Conclusions
Our results contrastwithpriormolecular imaging studies34,69
in bipolar disorder finding that dopamine synthesis and re-
leasecapacitywasunaltered.However, incontrast toourstudy,
neither of these prior studies included individuals with bipo-
lar illness with current psychosis, although one study34 in-
cludedpatientswithmania anddidnot find a relationship be-
tween manic symptoms and dopamine synthesis capacity.
Moreover, the association betweenKicer and psychotic symp-
toms inour sample remainedafter controlling formanic symp-
toms, suggesting that it was not driven by mania. Taken to-
gether with the previous results, our findings suggest that
elevated dopamine synthesis capacity is linked to psychosis
in bipolar disorder. However, a direct comparison between
individuals having bipolar disorder with vs without psycho-
sis is needed to definitively test the specificity of our findings
to psychosis in bipolar disorder. While we found an associa-
tion between dopamine synthesis capacity and bipolar psy-
chosis, this result does not imply causality. Further studies
are required to determine the relationship between dopa-
mine synthesis capacity and development of psychosis in
bipolar disorder.
We found that dopamine synthesis capacity is elevated in
psychotic bipolar affective disorder to a degree similar to that
inschizophreniaandis relatedtotheseverityofpsychotic (posi-
tive) symptoms. These results extend previous findings that
dopaminesynthesis capacity is elevated inschizophrenia11 and
psychosis associated with temporal lobe epilepsy10 and in-
creaseswith the onset of psychosis,15 suggesting that presyn-
apticdopaminedysfunction isassociatedwithpsychosisacross
diagnostic categories. This finding provides a potential neu-
robiological explanation for why antipsychotic drugs, which
are all dopamine D2/D3 receptor blockers, are effective in bi-
polarpsychosis andschizophrenia70-72 and identifies the regu-
lation of dopamine synthesis as a potential novel drug target
for bipolar disorder and schizophrenia.
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